I was in San Francisco last week, attending the American Chemical Society’s national meeting. They gave me their national writing award. This, to me, was both welcome and surprising. The ACS is not a group that I’ve been particularly close with over the years. In fact, sort of the opposite. It’s not a huge deal either way, but the story is this: The first major book I ever wrote (as a solo author) was Force of Nature: The Life of Linus Pauling, a biography of a former ACS President (and certified genius, and all-around great guy). After the book came out in 1995, it was only natural that one of the organization’s main magazines — Chemical and Engineering News — would review it.
They did. Unfortunately for me, it turned out to be the worst review the book got anywhere. It was written by an eminent chemist and colleague of Pauling’s — so far, so good — whom I had interviewed for the book and who showed up as a character. He didn’t like what I’d written about him (as I remember it, he was in one of one of the book’s darker chapters, quibbled over his portrayal, and didn’t like the quotes I’d used from our interview). The magazine’s decision to use a reviewer who is a character in the book seemed to me like a basic mistake, and I told the editor so. The response was more or less to be quiet and go away. I did not feel happy about this.
After that, the magazine ignored every book I wrote.
So it came as a nice surprise when the ACS informed me that they were giving me this year’s Grady-Stack award for Interpreting Chemistry for the Public. It’s kind of a big deal, given (along with many other scientific awards) at a big banquet, replete with tuxedos and steak. It was a lovely evening, with great people
The award came about because one man, Doug Dollemore, a former fellow UO Journalism School grad who now works at the ACS headquarters in Washington, D.C., pushed my nomination for years, and must have worn everybody down. Plus my books are just that good.
Thanks, Doug! I had a great time and enjoyed the banquet. And thanks, ACS!
Just signed a contract for a new book, a history of medicine told through the stories of ten blockbuster drugs, from opium to oxycontin, the smallpox vaccine to the Pill. I like the approach (can’t take credit for it, though — a smart editor proposed it to me), I like the structure, and I like the topic. Looking forward to it!
I just delivered a keynote speech and spent a few days soaking up new knowledge at the ARPA-E Energy Summit (ARPA-E is Advanced Research Projects Agency — Energy). It was great talking with some of the smartest, best-intentioned, most productive researchers I’ve ever met. The agency, set up by Obama seven years ago, seems like a brilliant concept: Put university researchers, entrepreneurs, corporate finance people, and government representatives in the same place at the same time, set them to work on a critical problem (creating cleaner, cheaper, more reliable, more resilient energy systems), and make it easy to form productive partnerships. Let starry-eyed dreamers learn a bit about the business world, and bring hard-nosed executives the latest developments in the nation’s labs. Find the best ideas and figure out how to fund them.
Too bad that, given the change in Administrations and Trump’s stubborn belief in “alternative facts”, this might be the last Summit. I really hope not.
One of the schools I graduated from, the University of Oregon, ran a piece this morning about my ACS award. Getting interviewed by two student journalists reminded me about what it was like when I was studying journalism, carefully writing questions, screwing up my courage to do an interview, stumbling through the Q&A, piecing together a story. Now, on the receiving end, I can better appreciate the shortfalls of short-form daily journalism, the bits and pieces selected and quotes shortened to fit, all the stuff that I’ve heard complaints about from just about anyone who’s had a news story written about them. The students here did a fine job; but my need to tell a fuller, more nuanced, more complete story was the main reason I was attracted to writing books rather than daily newspaper stories.
Very cool. It’s been a long time since I’ve been so excited about being invited to a meeting. But this is a special meeting, the ARPA-E Energy Innovation Summit, a chance to network with some of nation’s most innovative inventors and forward-looking business and government types, all dedicated to speeding our world toward better, cleaner, more efficient and sustainable energy systems. More about ARPA-E here. And check out my fellow speakers: summit-speakers-press-release-final-draft-11-28-2016. What a group! I’ll be talking about the lessons that old technology can teach us — Haber-Bosch and how a single breakthrough discovery can change the world — but spending most of my time checking out the stuff that might just usher in a new era. And one of my friends and I have been working on a few ideas of our own that you might be hearing more about later.
A recent debate about statins in the British medical press — Lancet vs. BMJ! Cage fight! — has me wondering about a bigger question: the limits to what physicians and others in the health industry call “evidence-based medicine.” Let’s shorten that to EBM, and see what the problem is.
EBM is usually defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients.” Hard to argue with that. Of course doctors should weigh what the current evidence says about a treatment before subjecting their patients to it. There may be questions about what is accepted as “evidence” and who defines what’s “best,” But that shouldn’t be too hard, either. Most physicians that I’ve talked to (and most people in general) would think that evidence means carefully conducted scientific studies, and best means most reproducible and consistent. As a science writer, I’m all in favor of basing things like medical treatment on scientific evidence. So yay EBM.
If there’s any place EBM should work, it’s in the arena of statins, the biggest-selling, most widely prescribed prescription medicines of our time. They are also the most studied, with hundreds of scientific papers assessing their risks and benefits.
So why are we still debating their proper use? It might come down to something that the admirable Ben Goldacre wrote a couple of years ago, “If there is any uncertainty at all about the risks and benefits of statins – and there is – then we have failed to competently implement the most basic principles of evidence based medicine.” In other words, the cure for this problem is more and better EBM.
But I don’t think it’s quite that. At least not only that. I encourage interested readers to read both sides of the statin debate summarized in the first link, as well as the bits that it links to. You’ll soon find yourself immersed — as I have been for the past few months — in a morass of evidence, a range of opinions about what that evidence means, and what appears to me to be a wall circumscribing EBM, a hard limit on what we can expect from basing medical practice on science. More studies — more EBM — won’t solve the problem.
Because the problem is rooted in places that EBM can’t go. In human greed and fallability, in our proclivity to adopt hard positions and defend them, in our personal ideas of what’s good for our society, and the ways in which these ideas conflict with others. EBM is misused by those who might profit from a particular angle, and when the stakes are high enough, will rarely lead to a consensus accepted by all. The same factors are at play in even bigger questions, like climate change. No amount of “evidence” is going to convince “skeptics.”
I spent several months going over the evidence about statins, and published my own reading of the issue here. (Spoiler alert: They are good for some people, bad for others; ; cause a bunch of side effects that range from annoying to life-threatening; can save many lives in high-risk groups but are relatively useless in populations who are at low-to-moderate risk of heart disease. There are equally effective, less risky alternatives for many patients. Bottom line: Statins are way, way, way overprescribed.)
That’s my opinion. It conflicts with the opinion of others. And as much as I hate to say it, I have little faith that the answer to that conflict will come from EBM.
Just found out some very good news: the American Chemical Society has announced its 2017 national award winners, and I’m among them. They’re giving me the Grady-Stack Award for interpreting chemistry for the public, the organization’s highest communications prize.
I’m really happy for a couple of reasons. First, because some of the science writers I admire most in this world — like the talented and tireless Deborah Blum, nobelist/poet Roald Hoffman, the brilliant Isaac Asimov, the dean of all science journalists Victor Cohn, and the man who originally inspired me to enter this field, Boyce Rensberger — are among the past recipients. It’s an incredible honor to be ranked in their number.
And second, because this is a seal of approval from those I write about, the scientists whose labors and insights are explored in my books. It’s a mark that my writing is true to its subjects as well as its readers. And that gets to the heart of what we all try to do in this science writing game: To bring to life, as accurately and completely as possible, the excitement and drama of science, and its value to our society.
Like I said, I’m really happy about this.
I’ve been spending a good part of the past eight months working on an experiment in publishing: The Naked Facts series. My son Jackson and I were sitting around one day, despairing of the wide range but generally poor quality of science information available on the internet to non-specialists. Say you’re looking for information on a drug you’ve been prescribed. Either you’re left with package-insert level info prepared by the drug company (and who reads those?), or some anti-drug screed written by alternative health practitioners, or chat rooms, or, if you know how to get them, research articles from journals. With rare exceptions either the info is slanted, or promotional, or too technical for non-specialists to read. So we decided to see if anyone would be interested in short, inexpensive, easy-to-read summaries of the best current knowledge about popular drugs and treatments, something that tried hard to be objective in approach, comprehensive in scope, but a quick, digestible summary of the essentials patients need to know to understand what they’re taking, and to have more productive conversations with their healthcare providers.
We’ve just published #6 in the series, on the world’s bestselling prescription drugs — statins. These are fascinating, sometimes miraculous, sometimes way overprescribed drugs, with a lot of pluses and minuses that most patients — and many physicians — don’t know about.
As an experiment in publishing, the results have been mixed so far. The books are just what I wanted: Simple, solid science, unlike anything else on the market. But sales have been slower than we want (perhaps because as a start-up company, we don’t have much money to put into marketing).
My book The Alchemy of Air traces the history of one of humanity’s greatest discoveries: How to make bread out of air. The Haber-Bosch process does that by turning air into fertilizer, using nitrogen and hydrogen. But it also creates a lot of air pollution, almost all of it from the process used to make pure hydrogen.
When Bosch designed the first plant to turn air into fertilizer around 1912, he made his hydrogen by electrolytically splitting apart water molecules, releasing pure hydrogen and oxygen. It was a pretty clean process. But it was also costly, because it took a lot of electricity to split the water.
So the industry moved to another source of hydrogen, which it still uses today: natural gas. Especially given today’s low prices for natural gas, it’s a lot cheaper to use than water. No wonder the entire nitrogen fertilizer industry is built around it. Problem is, purifying the hydrogen from natural gas releases a lot of CO2 along the way, making the industry a big polluter.
There might be an answer on the horizon. The trick will be making it easier to get H from H20, making it possible to get back to Bosch’s original vision of water-produced hydrogen. And a novel new approach to doing that has just been published. It is part of a wider effort to find catalysts that can make it easier for water to break into its constituent atoms. But this one is interesting because it’s temperature sensitive, allowing the catalyst to do part of its work effectively at one level, then do another part when the temperature is changed.
It’s no more than a theory at this time, but it’s an interesting theory. And it could open the door to a much, much cleaner fertilizer industry.